SEARCH:   Advanced

Blood, Vol. 113, Issue 22, 5549-5557, May 28, 2009 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell–mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach Blood Niedermeier et al. 113: 5549 Supplemental materials for: Niedermeier et al Files in this Data Supplement: Table S1. Clinical characteristics and risk factors of the CLL patients’ samples studied in this study (PDF, 56.0 KB) Table S2. Difference in viability between the combination treatment of PI3K inhibitors plus F-ara-A (PDF, 67.9 KB) - (A) In groups without M2-10B4. (B) And the two treatments alone in groups with M2-10B4. Table S3. Viability of normal peripheral blood mononuclear cells (PBMC) cultured with or without supportive stroma after treatment with PI3K-inhibitors alone or in combination with fludarabine (PDF, 110 KB) - Displayed are the mean relative viabilities of PBMC treated with the PI3K inhibitors and concentrations depicted on the horizontal axes, compared to untreated controls. “+F-ara-A“ indicates combination treatment with fludarabine. All experiments were either performed in suspension cultures (“w/o stroma”), or in co-cultures with marrow stromal cells (“+stroma”). Data repesent the means (± SEM) from 4 different donors. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020